STOCK TITAN

Cellyan Biotechnology chairman Lap Sun Wong resigns

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd. (HKPD) reported board and committee changes: Chairman and director Lap Sun Wong and independent director Zhao Letao tendered resignations on November 10, 2026. Upon the resignations taking effect, Wong’s chairman position became vacant. The company said neither resignation resulted from a disagreement over its operations, policies or practices.

CFO Shu Liu was appointed an executive director effective November 10, 2026. Independent director Xiaohu Quan was appointed on November 11, 2026, taking Zhao’s committee positions, including chair of the compensation committee. The company also said controlling shareholder Liying Wang changed her name to Aylin Ada; the name change does not affect her or entities she controls, including TUTU Business Services Limited, in relation to their rights, obligations, shareholding, beneficial ownership, interests, agreements or arrangements.

Board resignations November 10, 2026 Lap Sun Wong and Zhao Letao tendered their resignations on this date.
Executive director appointment November 10, 2026 Shu Liu was appointed executive director effective this date.
Independent director appointment November 11, 2026 Xiaohu Quan was appointed independent director effective this date.
Shu Liu’s age 30 years Age stated in her biographical information.
Xiaohu Quan’s age 33 years Age stated in his biographical information.
independent director regulatory
"appointed as an independent director of the Company"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Nasdaq Listing Rule 5605(a)(2) regulatory
"within the meaning of Nasdaq Listing Rule 5605(a)(2)"
Nasdaq Listing Rule 5605(a)(2) sets the criteria Nasdaq uses to decide whether a company’s board members are independent, listing examples of relationships or ties that would disqualify a director from being considered independent. Investors care because a board with genuinely independent directors acts like an impartial referee overseeing management decisions, reducing conflicts of interest and improving the chance that shareholder interests are protected and corporate decisions are scrutinized effectively.
Rule 10A-3 regulatory
"satisfies the independence requirements of Rule 10A-3"
beneficial ownership financial
"shareholding, beneficial ownership, interests, agreements or arrangements"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Name Equivalence Document technical
"a Name Equivalence Document issued by the General Directorate"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who left HKPD’s board in November 2026?

Chairman and director Lap Sun Wong and independent director Zhao Letao tendered their resignations on November 10, 2026. Wong’s chairman position became vacant upon his resignation taking effect.

Who joined HKPD’s board, and what committee roles did they take?

CFO Shu Liu was appointed an executive director effective November 10, 2026. Xiaohu Quan was appointed an independent director effective November 11, 2026, and took Zhao Letao’s committee positions, including membership on the audit, compensation, and nominating and corporate governance committees and chair of the compensation committee.

Did Aylin Ada’s name change affect her HKPD ownership?

No. Cellyan said the name change from Liying Wang to Aylin Ada did not affect her or entities she controls, including TUTU Business Services Limited, with respect to rights, obligations, shareholding, beneficial ownership, interests, agreements or arrangements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number 001-42468

 

CELLYAN BIOTECHNOLOGY CO., LTD

(Exact name of registrant as specified in its charter)

 

Cayman Islands

(Jurisdiction of incorporation or organization)

 

4/ Room B1, 5/F., Well Town Industrial Building,

13 Ko Fai Road, Yau Tong, Kowloon

Hong Kong

 

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

 

 

 

 

 

Information Contained in this Form 6-K Report

 

Resignation of Chairman and Director

 

On November 10, 2026, Mr. Lap Sun Wong (“Mr. Wong”) tendered his resignation as Chairman of the Board and as a director of Cellyan Biotechnology Co., Ltd. (the “Company”). Upon the effectiveness of his resignation, Mr. Wong ceased to serve as Chairman of the Board and as a director of the Company. Following Mr. Wong’s resignation, the Company no longer has a chairperson or Chairman of the Board, and the office of Chairman remains vacant unless otherwise resolved by the board of directors of the Company (the “Board”).

 

Mr. Wong has informed the Company that his resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

The Board would like to express its sincere gratitude to Mr. Wong for his contributions to the Company during his tenure of office.

 

Resignation of Independent Director

 

On November 10, 2026, Mr. Zhao Letao (“Mr. Zhao”) tendered his resignation as an independent director of the Company. Upon the effectiveness of his resignation, Mr. Zhao also ceased to serve as a member of the audit committee, the compensation committee and the nominating and corporate governance committee of the Board, and as chairman of the compensation committee of the Board.

 

Mr. Zhao has informed the Company that his resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

The Board would like to express its sincere gratitude to Mr. Zhao for his contributions to the Company during his tenure of office.

 

Appointment of Directors and Change in Composition of Board Committees

 

On November 10, 2026, the Board appointed Ms. Shu Liu (“Ms. Liu”) as an executive director of the Company with immediate effect. Ms. Liu currently serves as the Company’s Chief Financial Officer.

 

On November 11, 2026, the Board appointed Mr. Xiaohu Quan (“Mr. Quan”) as an independent director of the Company, effective November 11, 2026.

 

Mr. Quan was appointed to all positions held by Mr. Zhao immediately prior to Mr. Zhao’s resignation, including as a member of the audit committee, the compensation committee and the nominating and corporate governance committee of the Board, and as chairman of the compensation committee of the Board.

 

After the changes described above and effective from November 11, 2026:

 

●the Board consists of five (5) directors, including two (2) executive directors, namely Mr. Chenyu Liang and Ms. Liu, and three (3) independent directors, namely Ms. Jingyan Wu, Dr. Kam Leung Chan and Mr. Quan;

 

●Mr. Quan serves as a member of the audit committee, the compensation committee and the nominating and corporate governance committee of the Board, and as chairman of the compensation committee of the Board; and

 

●the Company does not have a chairperson or Chairman of the Board.

 

1

 

 

The Board has determined that Mr. Quan qualifies as an “independent director” within the meaning of Nasdaq Listing Rule 5605(a)(2) and satisfies the independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, based on an evaluation of the relationships between the Company and Mr. Quan.

 

Biographical Information

 

Ms. Shu Liu, aged 30, has been serving as the Chief Financial Officer of the Company since October 2025. Ms. Liu has rich experience in financial management and compliance, including key roles such as chief executive officer, investment advisors and finance manager with responsibilities encompassing accounting, budgeting, internal controls, and the implementation of financial systems. In August 2024, she served as chief executive officer at Shenzhen Yingdatongli Investment Group Co., Ltd., where she was responsible for the company’s acquisition work. From August 2023 to August 2024, she held an Investment Advisor position at Guosen Securities Co., Ltd., where she was responsible for providing advice to investors. Ms. Liu received a Master’s degree from Sun Yat-sen University in 2019 and qualified as an Intermediate Economist. Ms. Liu will contribute to the Company’s financial operations and ongoing compliance initiatives.

 

Mr. Xiaohu Quan, aged 33, since July 2026, Mr. Quan has been serving as a director of Jituo International Supply Chain Management Co., Ltd., where he leads the overseas trade business and is responsible for overseas channel development, cross-border supply chain operations, and supply chain system construction. From July 2019 to April 2025, Mr. Quan served as an overseas project supervisor at Huawei Technologies Co., Ltd., where he was responsible for overseas product sales management, overseas market expansion, and project operations. Mr. Quan has extensive management experience in cross-border supply chain operations. He holds a Master’s degree from Sun Yat-sen University.

 

Change of Name of Controlling Shareholder

 

The Company notes that Ms. Liying Wang, the Company’s controlling shareholder, has changed her name to Aylin Ada. The Company has received documentation evidencing the name change, including a Republic of Türkiye passport showing the name Aylin Ada and a Name Equivalence Document issued by the General Directorate of Population and Citizenship Affairs of the Republic of Türkiye dated November 6, 2026, showing the previous name LIYING WANG and the Turkish name AYLIN ADA.

 

The name change does not affect any rights, obligations, shareholding, beneficial ownership, interests, agreements or arrangements of or relating to Ms. Aylin Ada (formerly Liying Wang) or any entity controlled by her, including TUTU Business Services Limited.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CELLYAN BIOTECHNOLOGY CO., LTD
     
Date: November 12, 2026 By: /s/ Chenyu Liang
  Name: Chenyu Liang
  Title: Director and Chief Executive Officer

 

3

 

Keep reading